Hypoxia-activated KDAC inhibitor: Taking a breath from untargeted therapy

Use of hypoxia-activated prodrugs has emerged as a strategy for selectively targeting tumors in hypoxic conditions harboring reductive environments. In this issue of Cell Chemical Biology, Skwarska et al., 2021 Skwarska A. Calder E.D.D. Sneddon D. Bolland H. Odyniec M.L. Mistry I.N. Martin J. Folkes L.K. Conway S.J. Hammond E.M. Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor. Cell Chem. Biol. 2021;...